Concepedia

Kim Etchevers

KE

Statistics

Publications

2

Citations

30

H-Index

2

Active since

2020

Affiliations

Gilead Sciences (United States)(Current)

Kim Etchevers is an author at Gilead Sciences (United States) specializing in apoptosis, pharmacokinetics of anticancer drugs, and drug half-life.

Publications per year

2020–2025

2

Publications

2

Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects

Cara Nelson, Kim Etchevers, Saili Yi et al. · Clinical Pharmacokinetics · 2020 · 19 citations

, , +12

Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study

Onyema Ogbuagu, Jason D. Goldman, Robert Gottlieb et al. · The Lancet Infectious Diseases · 2025 · 11 citations · Full text

, , +12

1–2 of 2